テキサスにおけるホジキンリンパ腫の臨床試験
テキサス内の拠点で、ホジキンリンパ腫に関する15件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
被験者募集中第1相
12歳〜75歳 · 全性別 · 2026/10/02更新 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
被験者募集中第1相
12歳〜75歳 · 全性別 · 2026/10/02更新 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05615636Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/09/15更新 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/14更新 · NCT06137144Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT07444632Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
- UT MD Anderson, Houston
被験者募集中第2相
2歳〜21歳 · 全性別 · 2026/08/31更新 · NCT07551583Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳〜80歳 · 全性別 · 2026/08/07更新 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
被験者募集中第2相
15歳〜80歳 · 全性別 · 2026/07/30更新 · NCT02727803A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- 他5件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- 他1件
被験者募集中第1相
全年齢 · 全性別 · 2026/06/25更新 · NCT04664179A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
- MD Anderson Cancer Center, Houston
被験者募集中第2相健康なボランティア歓迎
1歳以上 · 全性別 · 2026/05/18更新 · NCT05355051Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
被験者募集中第1相
全年齢 · 全性別 · 2026/03/02更新 · NCT01555892Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。